LAVA Therapeutics
Quarterly Financials
| Values in thousands | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|
Revenue | $0 | $0 | $4,990 | $0 |
Gross Profit | -8 | -107 | -19,560 | -212 |
EBITDA | -8,559 | -3,018 | -3,109 | -11,073 |
EBIT | -8,567 | -3,125 | -3,196 | -11,285 |
Net Income | -8,639 | -3,479 | -3,969 | -12,296 |
Net Change In Cash | 0 | 0 | 4,990 | 0 |
Free Cash Flow | -13,749 | 2,025 | -1,405 | -8,653 |
Cash | 26,380 | 39,674 | 35,015 | 26,963 |
Basic Shares | 26,899 | 26,892 | 26,866 | 26,846 |
Annual Financials
| Values in thousands | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
Revenue | $11,982 | $6,769 | $19,391 | $5,000 |
Gross Profit | 11,982 | 3,287 | 19,391 | 5,000 |
EBITDA | -23,502 | -40,532 | -30,877 | -43,795 |
EBIT | -23,969 | -41,144 | -31,658 | -44,353 |
Net Income | -25,114 | -41,974 | -31,907 | -45,347 |
Net Change In Cash | 11,982 | 6,769 | 19,391 | 5,000 |
Free Cash Flow | -19,567 | -41,014 | 3,456 | -33,343 |
Cash | 35,015 | 44,231 | 100,333 | 151,013 |
Basic Shares | 26,834 | 26,732 | 25,924 | 19,758 |
Earnings Calls
| Quarter | EPS |
|---|---|
2025-09-30 | $0 |
2025-06-30 | -$0.32 |
2025-03-31 | -$0.11 |
2024-12-31 | -$0.12 |
